NCT04391556View on ClinicalTrials.gov

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

May 2, 2023

Study Completion Date

April 3, 2024

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Firmagon

120 mg subcutaneous Injection of Firmagon after a TEP-PSMA

Trial Locations (6)

13015

APHM - Hôpital Nord, Marseille

38700

Centre Hospitalier de Grenoble Hôpital Nord Michallon, La Tronche

63003

Chu Gabriel Montpied, Clermont-Ferrand

63011

Centre Jean Perrin, Clermont-Ferrand

69008

Centre Léon Bérard, Lyon

69310

Centre Hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT04391556 - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma | Biotech Hunter | Biotech Hunter